67Cu Radiopharmaceutical Formulation for Radiolysis and Stability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiolabelled compounds face issues such as premature dissociation of radioisotopes, radiolysis, unpredictable solubility, and instability due to varying radioactivity levels, which affect therapeutic efficacy and safety.
Innovation Solution
An aqueous formulation comprising a compound of Formula (I) complexed with 67Cu ion, including gentisic acid, ethanol, and ascorbic acid, with a pH between 4 and 8, maintains radiochemical purity and stability for at least 96 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the ligand and radioisotope are stored separately to minimise dissociation, then the stability of the complex is improved, but the complexity of the formulation process increases
Solution Approach 1:
The ligand is pre-complexed with a non-radioactive metal ion (such as copper, zinc, or calcium) before administration. This preliminary complexing action prevents premature dissociation of the radioisotope during transport and storage, while allowing the radioisotope to be added just before administration to maintain stability throughout the formulation process.
Solution Approach 2:
A non-radioactive metal ion acts as an intermediary component that facilitates stable complex formation between the ligand and radioisotope. This intermediary metal ion serves as a placeholder that maintains the ligand in a stable, ready state while allowing the radioisotope to be incorporated at the appropriate time without causing premature dissociation.
2Reliability
If the radioisotope is combined with the ligand just prior to administration, then the radiochemical purity is improved, but the time available for formulation development is reduced
Solution Approach 1:
The ligand is pre-complexed with a non-radioactive metal ion before administration, allowing formulation development to proceed in advance. The radioisotope is then added just before administration to maintain high radiochemical purity, effectively separating the formulation development phase from the final radiolabeling step.
Solution Approach 2:
The formulation process is segmented into two distinct phases: a pre-formulation phase where the ligand is complexed with a non-radioactive metal ion, and a final radiolabeling phase where the radioisotope is added just before administration. This segmentation allows for extended formulation development time while maintaining radiochemical purity.
3Productivity
If excipients are added to enhance solubility and stability, then the bioavailability is improved, but the complexity of the formulation increases
Solution Approach 1:
The non-radioactive metal ion serves multiple functions simultaneously: it acts as a placeholder to prevent premature dissociation, provides a stable complex structure for the ligand, and facilitates proper solubility and bioavailability. This multi-functionality reduces the need for multiple separate excipients, thereby reducing formulation complexity.
Solution Approach 2:
The formulation utilizes changes in metal ion coordination chemistry parameters to achieve optimal solubility and stability. By selecting appropriate non-radioactive metal ions and controlling the coordination environment, the formulation achieves enhanced bioavailability without requiring complex excipient systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures high radiochemical purity and stability, allowing delivery of high doses of radioactivity without degradation, suitable for diagnostic and therapeutic applications.
Implementation Method 1
the ligand comprises a component to complex the radioisotope
Implementation Method 2
As a radioisotope undergoes spontaneous decay and subsequent release of radiation, this energy may be sufficient to induce cleavage of bonds and cause subsequent destruction of the ligand
Implementation Method 3
the formulation further comprising a buffer and: about 0.01% to about 0.1% (w/v) gentisic acid or a salt thereof; about 1% to about 7% (v/v) ethanol; and about 4% to about 10% (w/v) ascorbic acid or a salt thereof
Data Source
AI summary
The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging. Specifically, the present invention relates to aqueous formulations of 67 Cu radiolabelled compounds of Formula (I) further comprising a buffer, gentisic acid, ethanol and ascorbic acid for use in radiotherapy and diagnostic imaging.